The effects of an ASA-like hydroperoxide compound on adenosine diphosphate induced platelet aggregation.
A hydroperoxide compound structurally related to acetylsalicylic acid, 3-hydroperoxy-3-methylphthalide, inhibits both the first and second phases of adenosine diphosphate induced, biphasic, human platelet aggregation. This occurs over the same concentration range (0.05-0.5 mM) that acetylsalicylic acid inhibits second phase aggregation and the release reaction only. The complete inhibition of adenosine diphosphate induced aggregation is a unique pharmacological property for an acetylsalicylic-acid-like compound.
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors*; D000255:Adenosine Triphosphate / Q000378:metabolism; D000328:Adult; D001241:Aspirin / Q000494:pharmacology*; D006801:Humans; D008875:Middle Aged; D010795:Phthalic Acids / Q000494:pharmacology*; D010796:Phthalic Anhydrides / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*
D010795:Phthalic Acids; D010796:Phthalic Anhydrides; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; C040698:3-hydroperoxy-3-methylphthalide; D001241:Aspirin